Year None202320222021202020192018 2/28/23 Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder 1/11/23 Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization 1/5/23 Landos Biopharma Provides Comprehensive Update on Clinical Development Plans 1/5/23 Landos Biopharma Announces $16.7 Million Private Placement Financing
2/28/23 Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
1/11/23 Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
